Northstar Asset Management Inc. Buys 27 Shares of IDEXX Laboratories, Inc. $IDXX

Northstar Asset Management Inc. boosted its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 0.1% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,992 shares of the company’s stock after purchasing an additional 27 shares during the quarter. IDEXX Laboratories comprises about 2.8% of Northstar Asset Management Inc.’s investment portfolio, making the stock its 15th largest holding. Northstar Asset Management Inc.’s holdings in IDEXX Laboratories were worth $10,186,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in IDXX. Price T Rowe Associates Inc. MD increased its holdings in IDEXX Laboratories by 71.0% in the first quarter. Price T Rowe Associates Inc. MD now owns 1,988,912 shares of the company’s stock valued at $835,244,000 after purchasing an additional 825,965 shares during the last quarter. Select Equity Group L.P. bought a new stake in IDEXX Laboratories in the first quarter valued at about $194,834,000. Nuveen LLC acquired a new position in IDEXX Laboratories in the first quarter valued at about $179,784,000. Principal Financial Group Inc. grew its stake in IDEXX Laboratories by 58.3% in the first quarter. Principal Financial Group Inc. now owns 1,126,002 shares of the company’s stock valued at $472,865,000 after acquiring an additional 414,802 shares during the period. Finally, Durable Capital Partners LP acquired a new position in IDEXX Laboratories in the first quarter valued at about $153,180,000. Institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Up 0.4%

IDXX stock opened at $640.85 on Friday. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. The stock has a market capitalization of $51.27 billion, a P/E ratio of 53.36, a P/E/G ratio of 4.13 and a beta of 1.58. The business has a 50-day moving average of $638.40 and a 200-day moving average of $557.79. IDEXX Laboratories, Inc. has a fifty-two week low of $356.14 and a fifty-two week high of $688.12.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Monday, August 4th. The company reported $3.63 EPS for the quarter, beating the consensus estimate of $3.28 by $0.35. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.The firm had revenue of $1.11 billion during the quarter, compared to analysts’ expectations of $1.06 billion. During the same period in the prior year, the firm posted $2.44 earnings per share. The business’s quarterly revenue was up 10.6% compared to the same quarter last year. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Morgan Stanley boosted their target price on IDEXX Laboratories from $722.00 to $765.00 and gave the company an “overweight” rating in a research note on Friday, August 15th. Weiss Ratings reissued a “buy (b-)” rating on shares of IDEXX Laboratories in a research note on Wednesday, October 8th. BTIG Research boosted their target price on IDEXX Laboratories from $545.00 to $785.00 and gave the company a “buy” rating in a research note on Tuesday, August 5th. Jefferies Financial Group assumed coverage on IDEXX Laboratories in a research note on Tuesday, July 1st. They issued a “buy” rating and a $625.00 target price for the company. Finally, UBS Group assumed coverage on IDEXX Laboratories in a research note on Wednesday, October 1st. They issued a “neutral” rating and a $720.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $656.50.

Insider Activity

In related news, EVP Nimrata Hunt sold 7,143 shares of the stock in a transaction that occurred on Wednesday, August 6th. The stock was sold at an average price of $630.43, for a total transaction of $4,503,161.49. Following the completion of the transaction, the executive vice president directly owned 18,007 shares of the company’s stock, valued at approximately $11,352,153.01. This represents a 28.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Jonathan Jay Mazelsky sold 29,260 shares of the stock in a transaction that occurred on Wednesday, August 6th. The shares were sold at an average price of $631.98, for a total value of $18,491,734.80. Following the transaction, the chief executive officer directly owned 83,311 shares of the company’s stock, valued at $52,650,885.78. This trade represents a 25.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 54,057 shares of company stock valued at $34,293,468. Corporate insiders own 0.98% of the company’s stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.